betaine has been researched along with Apoplexy in 11 studies
glycine betaine : The amino acid betaine derived from glycine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke." | 8.02 | Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021) |
| "Among our African-American participants, higher dietary choline intake was associated with a lower risk of incident ischemic stroke, and thus putative dietary benefits." | 7.88 | Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study. ( Bidulescu, A; Dibaba, DT; Millard, HR; Musani, SK; Talegawkar, SA; Taylor, HA; Tucker, KL, 2018) |
| "Increased TMAO was associated with higher stroke risk in the community-based population, whereas the TMAO precursors carnitine, choline, betaine, and TML were not associated." | 4.31 | Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study. ( Gu, S; Liu, D; Ma, Z; Zhou, Z; Zuo, H, 2023) |
| "We aimed to prospectively investigate the relationships of circulating choline and betaine with cardiovascular events and recurrent stroke in patients with ischemic stroke." | 4.02 | Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. ( Bu, X; Che, B; Du, J; He, J; Ju, Z; Miao, M; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2021) |
| "Among our African-American participants, higher dietary choline intake was associated with a lower risk of incident ischemic stroke, and thus putative dietary benefits." | 3.88 | Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study. ( Bidulescu, A; Dibaba, DT; Millard, HR; Musani, SK; Talegawkar, SA; Taylor, HA; Tucker, KL, 2018) |
| "Betaine is an osmolyte, supplies methyl groups, and controls plasma homocysteine." | 2.74 | Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. ( Chambers, ST; Elmslie, JL; Fink, JN; George, PM; Lever, M; Richards, AM; Scott, RS; Slow, S, 2009) |
| "TMAO was associated with lacunar stroke but not other ischemic stroke subtypes in a model adjusted for age, sex, hypertension, diabetes, and smoking (OR, 1." | 1.91 | Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke. ( Ament, Z; Bevers, MB; Bhave, VM; Couch, CA; Garcia Guarniz, AL; Irvin, MR; Kijpaisalratana, N; Kimberly, WT, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, D | 1 |
| Gu, S | 1 |
| Zhou, Z | 2 |
| Ma, Z | 1 |
| Zuo, H | 1 |
| Kijpaisalratana, N | 1 |
| Ament, Z | 1 |
| Bevers, MB | 1 |
| Bhave, VM | 1 |
| Garcia Guarniz, AL | 1 |
| Couch, CA | 1 |
| Irvin, MR | 1 |
| Kimberly, WT | 1 |
| Zhong, C | 1 |
| Miao, M | 1 |
| Che, B | 1 |
| Du, J | 1 |
| Wang, A | 1 |
| Peng, H | 1 |
| Bu, X | 1 |
| Zhang, J | 1 |
| Ju, Z | 1 |
| Xu, T | 1 |
| He, J | 1 |
| Zhang, Y | 1 |
| Yu, W | 1 |
| Xu, C | 1 |
| Li, G | 1 |
| Hong, W | 1 |
| Xiao, C | 1 |
| Zhao, Y | 1 |
| Cai, Y | 1 |
| Huang, M | 1 |
| Jin, J | 1 |
| Narayanan, D | 1 |
| Luvai, A | 1 |
| Barski, R | 1 |
| Sharma, R | 1 |
| Nagata, C | 1 |
| Wada, K | 1 |
| Tamura, T | 1 |
| Konishi, K | 1 |
| Kawachi, T | 1 |
| Tsuji, M | 1 |
| Nakamura, K | 1 |
| Skagen, K | 1 |
| Trøseid, M | 1 |
| Ueland, T | 1 |
| Holm, S | 1 |
| Abbas, A | 1 |
| Gregersen, I | 1 |
| Kummen, M | 1 |
| Bjerkeli, V | 1 |
| Reier-Nilsen, F | 1 |
| Russell, D | 1 |
| Svardal, A | 1 |
| Karlsen, TH | 1 |
| Aukrust, P | 1 |
| Berge, RK | 1 |
| Hov, JE | 1 |
| Halvorsen, B | 1 |
| Skjelland, M | 1 |
| Millard, HR | 1 |
| Musani, SK | 1 |
| Dibaba, DT | 1 |
| Talegawkar, SA | 1 |
| Taylor, HA | 1 |
| Tucker, KL | 1 |
| Bidulescu, A | 1 |
| Liu, P | 2 |
| Li, R | 1 |
| Antonov, AA | 1 |
| Wang, L | 2 |
| Li, W | 1 |
| Hua, Y | 1 |
| Guo, H | 1 |
| Chen, L | 1 |
| Tian, Y | 1 |
| Xu, F | 1 |
| Zhang, Z | 1 |
| Zhu, Y | 1 |
| Huang, Y | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Slow, S | 1 |
| Elmslie, JL | 1 |
| Scott, RS | 1 |
| Richards, AM | 1 |
| Fink, JN | 1 |
| Chambers, ST | 1 |
| Hewawasam, P | 1 |
| Ding, M | 1 |
| Chen, N | 1 |
| King, D | 1 |
| Knipe, J | 1 |
| Pajor, L | 1 |
| Ortiz, A | 1 |
| Gribkoff, VK | 1 |
| Starrett, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China[NCT01840072] | 4,071 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care | 502 |
| Active Antihypertensive Treatment | 500 |
Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks
| Intervention | participants (Number) |
|---|---|
| Usual Care | 681 |
| Active Antihypertensive Treatment | 683 |
Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months
| Intervention | MoCA score (Median) |
|---|---|
| Usual Care | 22 |
| Active Antihypertensive Treatment | 22 |
Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months
| Intervention | MMSE score (Median) |
|---|---|
| Usual Care | 26 |
| Active Antihypertensive Treatment | 26 |
Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months
| Intervention | Score on modified Rankin scale (Median) |
|---|---|
| Usual Care | 1.0 |
| Active Antihypertensive Treatment | 1.0 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 68 |
| Usual Care | 54 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Usual Care | 59 |
| Active Antihypertensive Treatment | 48 |
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Active Antihypertensive Treatment | 28 |
| Usual Care | 43 |
1 trial available for betaine and Apoplexy
| Article | Year |
|---|---|
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine.
Topics: Acute Coronary Syndrome; Aged; Betaine; Clofibric Acid; Cohort Studies; Diabetes Complications; Fema | 2009 |
10 other studies available for betaine and Apoplexy
| Article | Year |
|---|---|
Associations of plasma TMAO and its precursors with stroke risk in the general population: A nested case-control study.
Topics: Betaine; Carnitine; Case-Control Studies; Choline; Humans; Stroke | 2023 |
Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic Stroke.
Topics: Aged; Betaine; Carnitine; Cerebral Small Vessel Diseases; Choline; Cross-Sectional Studies; Female; | 2023 |
Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke.
Topics: Aged; Betaine; Cardiovascular Diseases; Case-Control Studies; Choline; Female; Humans; Lipotropic Ag | 2021 |
Simultaneous determination of trimethylamine N-oxide, choline, betaine by UPLC-MS/MS in human plasma: An application in acute stroke patients.
Topics: Aged; Betaine; Choline; Chromatography, High Pressure Liquid; Female; Humans; Male; Methylamines; Pl | 2018 |
Stroke in a young man.
Topics: Adult; Betaine; Cystathionine beta-Synthase; Diet, Protein-Restricted; Homocysteine; Homocystinuria; | 2013 |
Choline and Betaine Intakes Are Not Associated with Cardiovascular Disease Mortality Risk in Japanese Men and Women.
Topics: Adult; Animals; Asian People; Betaine; Choline; Coronary Disease; Diet; Female; Humans; Male; Middle | 2015 |
The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis.
Topics: Aged; Betaine; Biomarkers; Carnitine; Carotid Stenosis; Case-Control Studies; Cause of Death; Chroma | 2016 |
Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study.
Topics: Adult; Aged; Aged, 80 and over; Betaine; Black People; Cardiovascular Diseases; Choline; Coronary Di | 2018 |
Discovery of Metabolite Biomarkers for Acute Ischemic Stroke Progression.
Topics: Aged; Betaine; Biomarkers; Disease Progression; Early Diagnosis; Female; Humans; Isoleucine; Male; M | 2017 |
Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection.
Topics: Animals; Betaine; Blood; Carnitine; Crystallization; Dose-Response Relationship, Drug; Drug Stabilit | 2003 |